The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion.
The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said.
The latest deals, Sino Biopharmaceutical’s agreement with…
China biotech outlicensing tops US$52 billion in first 2 months after global deal surge
